Company description

Argenx SE is a biopharmaceutical company with a primary focus on developing innovative therapies for the treatment of severe autoimmune diseases and cancer. The company, with its ticker symbol ARGX, is headquartered in Belgium with additional offices in the Netherlands, US, and Japan. Its proprietary SIMPLE Antibody platform allows for the creation of differentiated, human-derived therapeutic antibodies that have the potential to overcome current treatment limitations. Argenx has a diverse portfolio of product candidates in various stages of development, including lead product candidate efgartigimod, which has received breakthrough therapy designation from the FDA for the treatment of myasthenia gravis. The company has also established partnerships with major pharmaceutical companies, such as AbbVie and Janssen, to advance their product candidates. With a strong commitment to scientific excellence and a dedicated team of experts, Argenx is poised to make a significant impact in the field of biopharmaceuticals and potentially improve the lives of patients worldwide.